Medtronic plc (MDT) Free Cash Flow (FCF): $5.43B
The free cash flow (FCF) for Medtronic plc (MDT) is $5.43B. It is above its 12-month average by 2.27% ($5.31B).
MDT Free Cash Flow (FCF) Chart
MDT Average Free Cash Flow (FCF) Chart
MDT Current vs Average Free Cash Flow (FCF) Chart
MDT Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$5.43B
FREE CASH FLOW (FCF) AVG TTM
$5.31B
FREE CASH FLOW (FCF) AVG 3Y
$5.10B
FREE CASH FLOW (FCF) AVG 5Y
$5.21B
FREE CASH FLOW (FCF) AVG 10Y
$5.14B
FREE CASH FLOW (FCF) AVG 15Y
$4.81B
FREE CASH FLOW (FCF) AVG 20Y
$4.27B
CURRENT VS TTM AVG
+2.27%
CURRENT VS 3Y AVG
+6.44%
CURRENT VS 5Y AVG
+4.17%
CURRENT VS 10Y AVG
+5.52%
CURRENT VS 15Y AVG
+12.85%
CURRENT VS 20Y AVG
+26.93%
FCF Analysis
Free Cash Flow (TTM)
$5.43B
FCF Yield
5.14%
Price/FCF
19.5
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Medtronic plc Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Medtronic plc (MDT)?
- The free cash flow (FCF) for MDT stock is $5.43B.
- What is the TTM average free cash flow (FCF) for Medtronic plc (MDT)?
- The TTM average free cash flow (FCF) for MDT stock is $5.31B.
- What is the 3Y average free cash flow (FCF) for Medtronic plc (MDT)?
- The 3Y average free cash flow (FCF) for MDT stock is $5.10B.
- What is the 5Y average free cash flow (FCF) for Medtronic plc (MDT)?
- The 5Y average free cash flow (FCF) for MDT stock is $5.21B.
- What is the 10Y average free cash flow (FCF) for Medtronic plc (MDT)?
- The 10Y average free cash flow (FCF) for MDT stock is $5.14B.
- What is the 15Y average free cash flow (FCF) for Medtronic plc (MDT)?
- The 15Y average free cash flow (FCF) for MDT stock is $4.81B.
- What is the 20Y average free cash flow (FCF) for Medtronic plc (MDT)?
- The 20Y average free cash flow (FCF) for MDT stock is $4.27B.
Medtronic plc Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2026-04-24 | $5.43B |
| 2025-04-30 | $5.18B |
| 2024-04-30 | $5.20B |
| 2023-04-30 | $4.58B |
| 2022-04-30 | $5.98B |
| 2021-04-30 | $4.88B |
| 2020-04-30 | $6.02B |
| 2019-04-30 | $5.87B |
| 2018-04-30 | $3.62B |
| 2017-04-30 | $5.63B |
| 2016-04-30 | $4.17B |
| 2015-04-30 | $4.33B |
| 2014-04-30 | $4.56B |
| 2013-04-30 | $4.43B |
| 2012-04-30 | $3.85B |
| 2011-04-30 | $3.19B |
| 2010-04-30 | $3.50B |
| 2009-04-30 | $3.21B |
| 2008-04-30 | $2.88B |
| 2007-04-30 | $2.29B |
| 2006-04-30 | $963.20M |
| 2005-04-30 | $2.37B |
| 2004-04-30 | $2.42B |
| 2003-04-30 | $1.70B |
| 2002-04-30 | $1.20B |
| 2001-04-30 | $1.39B |
| 2000-04-30 | $699.90M |
| 1999-04-30 | $-788.50M |
| 1998-04-30 | $441.90M |
| 1997-04-30 | $273.40M |
Related Metrics
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha